Lyell Immunopharma, Inc. (LYEL) Profit Margins
Over the twelve months to 2026-06-30, Lyell Immunopharma, Inc. (LYEL) had operating margin -949981.5%, net margin -920285.2%, free cash flow margin -496188.9%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LYELLyell Immunopharma, Inc.Follow LYEL — free
—
Price chart with a free account
- Market cap
- 230.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating margin | -2016.7% | -220.9% | -190006.2% | -588123.0% | -748344.4% | -949981.5% | |
| Net margin | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% | -920285.2% | |
| FCF margin | -1800.5% | -228.9% | -127984.6% | -266980.3% | -418900.0% | -496188.9% |
USD billions · SEC XBRL
Lyell Immunopharma, Inc. — questions
- What is Lyell Immunopharma, Inc.'s operating margin?
- -949981.5% over the twelve months to 2026-06-30.
- What is Lyell Immunopharma, Inc.'s net profit margin?
- -920285.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Lyell Immunopharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.